Evidence map›Paper›PMID 36556410›Full record

ArticleLife (Basel, Switzerland)2022

Effects of Taxifolin in Spontaneously Hypertensive Rats with a Focus on Erythrocyte Quality.

Tomas Jasenovec, Dominika Radosinska, Marta Kollarova, Peter Balis, Stefan Zorad, Norbert Vrbjar, Iveta Bernatova, Sona Cacanyiova, Lubomira Tothova, Jana Radosinska

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tomas JasenovecInstitute of Physiology, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, Slovakia.
Dominika RadosinskaInstitute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Marta KollarovaInstitute of Physiology, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, Slovakia.ORCID 0000-0002-0023-1541
Peter BalisCentre of Experimental Medicine, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
Stefan ZoradInstitute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
Norbert VrbjarCentre of Experimental Medicine, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
Iveta BernatovaCentre of Experimental Medicine, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.ORCID 0000-0002-6120-706X
Sona CacanyiovaCentre of Experimental Medicine, Slovak Academy of Sciences, 841 04 Bratislava, Slovakia.
Lubomira TothovaInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Jana RadosinskaInstitute of Physiology, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, Slovakia.ORCID 0000-0001-6703-5863
Slovak Academy of Sciences · SKComenius University Bratislava · SK

Funding

Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA1/0193/21Slovak Research and Development Agency APVV-18-0287Slovak Research and Development Agency APVV PP-COVID-20-0043
6 · The paper itself

Abstract

Oxidative stress and multiple erythrocyte abnormalities have been observed in hypertension. We focused on the effects of angiotensin-converting enzyme 2 (ACE2) inhibition by MLN-4760 inhibitor on angiotensin peptides, oxidative stress parameters, and selected erythrocyte quality markers in spontaneously hypertensive rats (SHR). We also investigated the potential effects of polyphenolic antioxidant taxifolin when applied in vivo and in vitro following its incubation with erythrocytes. SHRs were divided into four groups: control, taxifolin-treated, MLN-4760-treated, and MLN-4760 with taxifolin. MLN-4760 administration increased the blood pressure rise independent of taxifolin treatment, whereas taxifolin decreased it in control SHRs. Body weight gain was also higher in ACE2-inhibited animals and normalized after taxifolin treatment. However, taxifolin did not induce any change in angiotensin peptide concentrations nor a clear antioxidant effect. We documented an increase in Na,K-ATPase enzyme activity in erythrocyte membranes of ACE2-inhibited SHRs after taxifolin treatment. In conclusion, ACE2 inhibition deteriorated some selected RBC properties in SHRs. Although taxifolin treatment did not improve oxidative stress markers, our data confirmed the blood pressure-lowering potential, anti-obesogenic effect, and some "erythroprotective" effects of this compound in both control and ACE2-inhibited SHRs. In vitro investigations documenting different effects of taxifolin on erythrocyte properties from control and ACE2-inhibited SHRs accentuated the irreplaceability of in vivo studies.

Indexed as

ACE2erythrocyteshypertensionNa,K-ATPasenitric oxideosmotic resistanceoxidative stressrenin–angiotensin systemtaxifolin

Identifiers

PMID36556410
PMCPMC9788412
OpenAlexW4311728769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.